ID

38766

Descrição

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT01691755

Link

https://clinicaltrials.gov/show/NCT01691755

Palavras-chave

Versões (2)
  1. 02/11/2019 02/11/2019 -
  2. 02/11/2019 02/11/2019 -
Titular dos direitos

See clinicaltrials.gov

Transferido a

2 de novembro de 2019

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0
Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Voltar para os comentários do modelo
Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Diabetes Mellitus, Type 2 NCT01691755

Inglês

Eligibility Diabetes Mellitus, Type 2 NCT01691755

1 Formulários  
Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
adult patients, >/=18 years of age
Descrição

Adult | Age

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0001675
UMLS CUI [2]
C0001779
diagnosis of diabetes mellitus, type 2 within 12 months prior to screening
Descrição

Non-Insulin-Dependent Diabetes Mellitus Disease length

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0011860
UMLS CUI [1,2]
C0872146
patients who have not received a anti-hyperglycemic medication for at least 12 weeks prior to screening and for not longer than 3 consecutive months in the past
Descrição

Hypoglycemic Agents Absent

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0020616
UMLS CUI [1,2]
C0332197
hba1c >/=7% and </=9.5% at screening or within 4 weeks prior to screening and at pre-randomization visit
Descrição

Hemoglobin A1c measurement

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0474680
fasting plasma glucose </=240 mg/dl at pre-randomization visit
Descrição

Plasma fasting glucose measurement

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0583513
agreement to maintain diet and exercise habits during the study
Descrição

Diet therapy Maintenance | Exercise Habits Maintenance

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0012159
UMLS CUI [1,2]
C0024501
UMLS CUI [2,1]
C0015259
UMLS CUI [2,2]
C0018464
UMLS CUI [2,3]
C0024501
Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients with type 1 diabetes mellitus, secondary diabetes, diabetes resulting from pancreatic injury, or acute metabolic diabetic complications within the past 6 months
Descrição

Diabetes Mellitus, Insulin-Dependent | Secondary diabetes mellitus | Diabetes Mellitus Due to Injury of pancreas | Complications of Diabetes Mellitus Metabolic

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0011854
UMLS CUI [2]
C0271640
UMLS CUI [3,1]
C0011849
UMLS CUI [3,2]
C0678226
UMLS CUI [3,3]
C0273163
UMLS CUI [4,1]
C0342257
UMLS CUI [4,2]
C0311400
any previous treatment with thiazolidinedione or a dual ppar agonist
Descrição

Thiazolidinediones | Peroxisome Proliferator-Activated Receptor Agonist Dual

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1257987
UMLS CUI [2,1]
C0166418
UMLS CUI [2,2]
C2987634
UMLS CUI [2,3]
C0205173
any body weight lowering or lipoprotein-modifying therapy within 12 weeks prior to screening (except stable dose of statin)
Descrição

Weight reduction regimen | Lipoprotein modification Therapy | Exception Statins Dose Stable

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0311130
UMLS CUI [2,1]
C1158918
UMLS CUI [2,2]
C0087111
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0360714
UMLS CUI [3,3]
C0178602
UMLS CUI [3,4]
C0205360
symptomatic congestive heart failure classified as new york heart association class ii-iv at screening
Descrição

Symptomatic congestive heart failure New York Heart Association Classification

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0742758
UMLS CUI [1,2]
C1275491
Voltar ao início da página

Similar models

Eligibility Diabetes Mellitus, Type 2 NCT01691755

1 Formulários
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
Adult | Age
Item
adult patients, >/=18 years of age
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Non-Insulin-Dependent Diabetes Mellitus Disease length
Item
diagnosis of diabetes mellitus, type 2 within 12 months prior to screening
boolean
C0011860 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
Hypoglycemic Agents Absent
Item
patients who have not received a anti-hyperglycemic medication for at least 12 weeks prior to screening and for not longer than 3 consecutive months in the past
boolean
C0020616 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Hemoglobin A1c measurement
Item
hba1c >/=7% and </=9.5% at screening or within 4 weeks prior to screening and at pre-randomization visit
boolean
C0474680 (UMLS CUI [1])
Plasma fasting glucose measurement
Item
fasting plasma glucose </=240 mg/dl at pre-randomization visit
boolean
C0583513 (UMLS CUI [1])
Diet therapy Maintenance | Exercise Habits Maintenance
Item
agreement to maintain diet and exercise habits during the study
boolean
C0012159 (UMLS CUI [1,1])
C0024501 (UMLS CUI [1,2])
C0015259 (UMLS CUI [2,1])
C0018464 (UMLS CUI [2,2])
C0024501 (UMLS CUI [2,3])
Item Group
C0680251 (UMLS CUI)
Diabetes Mellitus, Insulin-Dependent | Secondary diabetes mellitus | Diabetes Mellitus Due to Injury of pancreas | Complications of Diabetes Mellitus Metabolic
Item
patients with type 1 diabetes mellitus, secondary diabetes, diabetes resulting from pancreatic injury, or acute metabolic diabetic complications within the past 6 months
boolean
C0011854 (UMLS CUI [1])
C0271640 (UMLS CUI [2])
C0011849 (UMLS CUI [3,1])
C0678226 (UMLS CUI [3,2])
C0273163 (UMLS CUI [3,3])
C0342257 (UMLS CUI [4,1])
C0311400 (UMLS CUI [4,2])
Thiazolidinediones | Peroxisome Proliferator-Activated Receptor Agonist Dual
Item
any previous treatment with thiazolidinedione or a dual ppar agonist
boolean
C1257987 (UMLS CUI [1])
C0166418 (UMLS CUI [2,1])
C2987634 (UMLS CUI [2,2])
C0205173 (UMLS CUI [2,3])
Weight reduction regimen | Lipoprotein modification Therapy | Exception Statins Dose Stable
Item
any body weight lowering or lipoprotein-modifying therapy within 12 weeks prior to screening (except stable dose of statin)
boolean
C0311130 (UMLS CUI [1])
C1158918 (UMLS CUI [2,1])
C0087111 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0360714 (UMLS CUI [3,2])
C0178602 (UMLS CUI [3,3])
C0205360 (UMLS CUI [3,4])
Symptomatic congestive heart failure New York Heart Association Classification
Item
symptomatic congestive heart failure classified as new york heart association class ii-iv at screening
boolean
C0742758 (UMLS CUI [1,1])
C1275491 (UMLS CUI [1,2])
Voltar ao início da página 

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial